| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | LAQ824 | GDSC1000 | pan-cancer | AAC | 0.099 | 0.004 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.11 | 0.004 |
| mRNA | CCT018159 | GDSC1000 | pan-cancer | AAC | 0.098 | 0.005 |
| mRNA | shikonin | GDSC1000 | pan-cancer | AAC | 0.096 | 0.005 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.15 | 0.005 |
| mRNA | BAY 61-3606 | GDSC1000 | pan-cancer | AAC | 0.093 | 0.007 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | 0.089 | 0.008 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.096 | 0.008 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.1 | 0.008 |